AngioDynamics, Inc. (ANGO)

NMS – Real Time Price. Currency in USD

15.53

-0.22 (-1.40%)

Market open: Aug 12, 2026, 10:52 AM EDT

15.75

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

11.08.2026

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.

06.08.2026

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

06.08.2026

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.

06.08.2026

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.

Videos

No Data

There is no data to display

AngioDynamics, Inc. (ANGO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AngioDynamics, Inc. (ANGO)

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

Videos

No Data

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

Videos

No Data

Search stocks

AngioDynamics, Inc. (ANGO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AngioDynamics, Inc. (ANGO)

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

Videos

No Data

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

Videos

No Data